医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ID-Solutions S.r.l. Becomes Murata ID Solutions S.r.l.

2020年02月14日 AM10:00
このエントリーをはてなブックマークに追加


 

KYOTO, Japan

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) (hereafter “Murata”), announces the change of the company name of its affiliate ID-Solutions S.r.l. (Headquarters: Parma, Italy), to Murata ID Solutions S.r.l., effective April 1, 2020.

Murata ID Solutions is a RFID system integrator that, starting from their consultancy experience and development of their own middleware and application software, provides added value traceability solutions based on customer needs. The company was acquired by Murata on June 1, 2017.

The name change will rebrand the company’s corporate image as a member of the Murata Group and enhance the RFID business through greater synergies.

New corporate name of the company: Murata ID Solutions S.r.l.

Current corporate name of the company: ID-Solutions S.r.l.

Brief summary

Company name: Murata ID Solutions S.r.l.

Location: Viale Mariotti, 1 43121 Parma
Representative: Antonio Rizzi
Business description: RFID system integration (including middleware and application software development)
Number of employees: 17
Main office: Parma, Italy
http://www.murata-idsolutions.com/

Related news release

Murata acquired ID-Solutions in Italy
https://www.murata.com/en-global/about/newsroom/news/company/general/2017/0602

Murata in Brief

Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. For more information, visit Murata’s website at www.murata.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005014/en/

CONTACT

For more information, please contact:

Murata Manufacturing Co., Ltd.

Nobuhiko Iida, prsec_mmc@murata.com

Corporate Communications Department

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
  • 武田薬品、ALK陽性転移性非小細胞肺がんに対するファーストライン治療薬としてのALUNBRIG®(ブリガチニブ)の適応追加申請を米国FDAが優先審査に指定と発表
  • Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease
  • 武田宣布美国FDA授予ALUNBRIG® (brigatinib)作为ALK+转移性非小细胞肺癌一线治疗的补充新药申请优先审理
  • Arima Genomics完成A轮融资